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Neovascularization is a complex process and is tightly
regulated by many positive and negative factors [1-3]. It plays
important roles in several diseases of the eye, resulting in
vision  impairment  or  blindness.  The  cornea  is  normally
avascular to permit optimal visual clarity; neovascularization,
however,  can  occur  in  pathologic  conditions.  Corneal
neovascularization (corneal NV) is a central feature in the
pathogenesis of many blinding corneal disorders and is also a
major  sight-threatening  complication  in  corneal  infections
and  chemical  injury  or  after  keratoplasty.  Effective  and
practical approaches to diminishing or completely preventing
corneal NV remain to be found. Anti-angiogenic therapy may
serve as a strategy for such ocular disease therapy. Since
increased  secretion  of  vascular  endothelial  growth  factor
(VEGF) [4-6] has been observed in corneal NV as well as in
other ocular neovascularization, some of the efforts have been
directed at blocking VEGF or its endothelial cell-specific
receptors, namely vascular endothelial growth factor receptor
1 (Flt-1) and vascular endothelial growth factor receptor 2
(Flk-1).  Thus  VEGF-targeted  neutralizing  antibodies,
antisense  oligonucleotides,  soluble  receptors,  or  nuclease-
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resistant  aptamers  have  been  reported  to  inhibit
neovascularization in laboratory research or clinical practice
[7-11].
Activation of nuclear factor-κB (NF-κB) reportedly leads
to  the  expression  of  VEGF  [12-14].  Deletion  of  NF-κB
binding sites within the VEGF promoter abolishes VEGF
expression in many cells, suggesting that activation of NF-
κB  is  essential  for  VEGF  upward  regulation  induced  by
various stimuli [15]. Other angiogenesis or anti-angiogenesis
pathways  are  also  important  in  the  development  of
neovascularization.  For  example,  endostatin  (Endo)  is  an
endogenous  inhibitor  of  angiogenesis  [16].  Systemic
administration of Endo by gene delivery resulted in reduced
corneal  NV  during  36  days  posttransplantation  [17].  The
angiopoietin(Ang)–Tie2  system  in  endothelial  cells  also
participates in vasculogenesis and maintenance of vascular
integrity. Ang1 and Ang2 have been identified as ligands of
the endothelial cell-specific Tie2 receptor [18,19]. Targeted
gene inactivation in vivo or transgenic overexpression studies
suggest  that  Ang1  recruits  and  sustains  periendothelial
support cells, while Ang2 disrupts blood vessel formation in
the developing embryo by antagonizing the effects of Ang1
on  Tie2  [19,20].  Targeting  the  Ang–Tie2  pathway  with
soluble  Tie2  (sTie2)  has  been  shown  to  block  tumor
angiogenesis  [21],  and  nuclease-resistant  RNA  aptamer
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Purpose: To determine the effectiveness of multigene-based anti-angiogenic gene therapies for experimental murine
corneal neovascularization (corneal NV).
Methods: Recombinant retroviral vectors encoding murine endostatin (mEndo), murine-soluble vascular endothelial
growth factor receptor-2 (msFlk-1), or murine-soluble Tie2 (msTie2) were constructed and packaged in PT67 cells. Viral
titers were determined by infection of NIH3T3 cells. Expressions of mEndo, msFlk-1, and msTie2 were confirmed by
reverse transcription PCR. The 3-(4,5-Dimethyl-2-thiazolyl-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay was used
to estimate the effect of mEndo, msFlk-1, or msTie2 on the proliferation of human umbilical vein endothelial cells, and
the scarification test was used to measure the migration of the cells. Seventy C57Bl/6 mice were subjected to the induction
of chemical-burn corneal NV and tested for efficacy of gene therapy. Gene therapy was performed by subconjunctival
injection of viral preparations and its effect was evaluated by scoring corneal NV.
Results:  The  recombinant  virus-producing  cell  lines  expressing  mEndo,  msFlk-1,  and  msTie2  were  constructed
successfully. Overexpression of these putative anti-angiogenic proteins inhibited the proliferation and migration of human
umbilical vein endothelial cells in vitro. In the murine corneal NV model, subconjunctival injection of the retroviral
particles of mEndo and msFlk-1 showed the most significant inhibition of corneal NV.
Conclusions: Gene therapy with the recombinant retroviral vector-hosted mEndo and msFlk-1 gene effectively inhibited
corneal NV induced by alkaline burn. The combination of multiple anti-angiogenic genes might be necessary for effective
therapy of corneal NV, although each of these pathways makes a potential target for the treatment of this disease.specific for Ang2 also inhibits rat corneal neovascularization
[22].
Although successful anti-angiogenic therapies have been
demonstrated  in  animal  neovascularization  models  with
certain  factors,  systematic  comparisons  of  the  potency  of
different  anti-angiogenic  factors  in  corneal  NV  situations
have not been described. While therapy targeting a single anti-
angiogenic  gene  cannot  block  corneal  NV  development
completely [23], we tried to explore optimal combinations of
multigene-based anti-angiogenic therapies for corneal NV. In
this  study,  we  investigated  the  anti-angiogenic  activity  of
strategies targeting VEGF, Tie2, and Endo to inhibit alkaline
burn-induced corneal NV in mice.
METHODS
Generation of retroviral particles: The retroviral expression
vector  used  in  this  study  was  pMSCV  (BD  BioSciences
Clontech, San Jose, CA), a Moloney murine leukemia-virus-
derived  retroviral  vector  capable  of  prolonged  transgene
expression in vivo through a modified long-terminal repeat
(LTR). The DNA fragments of murine endostatin (mEndo),
murine-soluble vascular endothelial growth factor receptor 2
(msFlk-1) and murine-soluble Tie2 (msTie2) were generated
by polymerase chain reaction (PCR). Recombinant retroviral
vectors hosting mEndo, msFlk-1, or msTie2 were constructed
as described previously [24] and transfected into PT67 cells,
using  Effectence  Transfection  Reagent  (Qiagen  GmbH,
Hilden,  Germany).  Transfected  PT67  cells  were  selected
against puromycine (2 μg/ml), and the stable transfectants
were  expanded  and  named  vehicle  vector-PT67,  mEndo-
PT67,  msFlk-1-PT67,  and  msTie2-PT67.  Virus-containing
culture supernatants were collected and filtered through a
0.45-μM filter unit. Viral titers were determined by infection
of NIH3T3 cells, as described by others [25] and adjusted to
5×106  plaque-forming  units  (pfu)/ml.  NIH3T3  cells  were
plated at 2.5×105 in a 60 mm dish on the previous day. To
determine viral titer, serially diluted viral supernatants were
added to NIH3T3 in the presence of 8 μg/ml polybrene. The
next day, transduced cells were transferred to 100 mm plates
and  selected  in  the  presence  of  puromycine  until  visible
colonies were formed. Viral titer was determined by counting
the number of drug-resistant colonies. The retrovirus was
purified  by  using  ViraTrapTM  retrovirus  purification  kit
(Biomiga, San Diego, CA) as follows: One to two T75 flasks
of the retrovirus-infected culture media were centrifuged at
1,000× g for 10 min. The column was equilibrated with 2 ml
of double-distilled water and then with 5 ml of 1× kit wash
buffer.  The  supernatant  was  loaded  onto  the  column  and
allowed  to  gradually  run  through.  The  flow  through  was
collected and reloaded to the same column one more time to
ensure maximal viral particle binding. The column was then
washed,  and  the  retrovirus  was  eluted.  The  titer  of  the
concentrated viral stock was 1×107 pfu/ml. The virus was
stored at −70 °C for further use.
Infection  of  human  umbilical  vein  endothelial  cells  and
detection of proliferation and migration: Human umbilical
vein endothelial cells (HUVEC) were seeded in 96-well plates
at 2,500 cells per well in 100 μl of DMEM (Gibco, Grand
Island, NY) complete medium (plus 10% fetal calf serum) 1
day before transfection. Viral supernatant containing vehicle
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Figure  1.  Effect  of  murine  endostatin  (mEndo),  murine-soluble
vascular endothelial growth factor receptor 2 (msFlk-1), and murine-
soluble Tie2 (msTie2) expression on proliferation and migration of
HUVEC cells. A: Equal numbers of HUVEC cells were incubated
for 24 h in viral supernatant from vehicle vector-PT67, mEndo-PT67,
msFlk-1-PT67, or msTie2-PT67 cells. The viable cell number was
measured  by  the  conversion  during  4  h  of  MTT  into  soluble
formazan. Bars represent standard deviation (SD; n=3 wells per
measurement). Similar results were obtained in three independent
experiments. B: HUVEC cells were seeded on 24-well tissue culture
plates. When the cells reached 90% confluence, a wound was made
with a micropipette tip in the center of the culture plates. The cultures
were rinsed to remove detached cells and incubated with medium
containing  viral  supernatant  from  vehicle  vector-PT67,  mEndo-
PT67, msFlk-1-PT67, or msTie2-PT67 cells for 16 h. Digital images
of wound closure were captured and used for quantitative assessment
of migration by measuring the distance cells migrated beyond the
injury lines. Four independent experiments were conducted, and data
were shown as mean±SD. The asterisk indicates p<0.05, and the
double asterisk indicates p<0.01, compared with vehicle vector cells.For the measurement of cell migration, a wound-healing
assay was used [26]. Briefly, HUVEC cells were seeded on
24-well tissue culture plates. When the culture reached 90%
confluence, a wound was made with a micropipette tip in the
center of the culture plates. The cultures were rinsed with
culture medium to remove detached cells and incubated with
medium containing viral supernatant from vehicle vector-
PT67, mEndo-PT67, msFlk-1-PT67, or msTie2-PT67 cells
for  another  16  h.  Digital  images  of  wound  closure  were
obtained and used for quantitative assessment of migration by
measuring  the  distance  of  cells  that  migrated  beyond  the
original injury borders. Each assay was conducted at least in
triplicate.
Induction  of  cornea  neovascularization  and  therapy:  All
animal experiments were performed in accordance with the
guidelines  of  the  Association  for  Research  in  Vision  and
Ophthalmology  Statement  for  the  Use  of  Animals  in
Ophthalmic and Vision Research. Seventy C57B1/6 mice of
both  sexes  (male:female=1:1),  8–10–weeks  old,  were
purchased  from  the  Institution  of  Laboratory  Animal
Sciences, Chinese Academy of Medical Sciences (Beijing,
China) and were housed at the Shandong Eye Institute Animal
Facility. Briefly, the mice were anesthetized intraperitoneally
with  ketamine  (37.5  mg/ml)  and  xylazine  (1.9  mg/ml).
Proparacaine  hydrochloride  (0.5%)  was  used  for  topical
anesthesia. For induction of corneal NV, a piece of disk-
shaped filter paper 2.0 mm in diameter was immersed in 1
mol/l NaOH solution for 15 s and placed on the central corneal
surface  for  50  s  to  produce  a  circular  burn,  followed  by
immediate washing with 30 ml of 0.9% saline. Only the right
eye of each mouse was used for corneal NV induction; the left
eye was undisturbed. For gene therapy, viral preparations
were injected into the subconjunctival site on the same day of
the corneal NV induction. Briefly, a needle pierced into the
conjunctiva from the corneoscleral limbus, and 7 μl of purified
retroviral  particles  (1×107  pfu/ml)  or  saline  was  injected.
Thirty-six  hours  following  the  operation,  another  7  μl  of
retroviral particles was administrated into the conjunctival
sac. The contents of each retroviral particle in every group
were as follows: normal group, untreated; saline group, 7 μl
of  0.9%  saline;  vehicle  vector,  7  μl  of  vehicle  retroviral
particles;  msFlk-1/msTie2,  3.5  μl  of  msFlk-1  retroviral
particles and 3.5 μl of msTie2 retroviral particles; msFlk-1/
mEndo, 3.5 μl of msFlk-1 retroviral particles and 3.5 μl of
mEndo retroviral particles; msTie2/mEndo, 3.5 μl of msTie2
retroviral particles and 3.5 μl of mEndo retroviral particles;
msFlk-1/msTie2/mEndo,  2.3  μl  of  msFlk-1  retroviral
particles, 2.3 μl of msTie2 retroviral particles, and 2.3 μl of
mEndo  retroviral  particles.  Each  group  contained  ten
C57B1/6 mice. Eyes were examined daily under a slit-lamp
biomicroscope (Zeiss, Jena, Germany) for 7 days from the
alkaline burn. Cornea photographs were taken with a camera
mounted  on  the  slit-lamp  microscope  under  the  same
magnification.  Neovascularization  of  each  cornea,  as
described by others [27], was determined by a blind examiner
to  minimize  the  observer’s  bias.  Briefly,  the
neovascularization score=(distance from the limbus to the end
point  of  the  cornea  neovascularization/distance  from  the
limbus to burn)/0.17. Each cornea received an exact score.
Scores  were  concluded  representatively  as  follows:  0  (no
visible vessels in the cornea), +1.5 (1/4 distance to burn), +2
(1/3 distance to burn), +3 (1/2 distance to burn), +4 (2/3
distance to burn), +4.5 (3/4 distance to burn), and +6 (vessels
reach burn).
Reverse-transcription PCR: Total RNA was prepared from
each cornea, using the NucleospinRNA kits (BD Biosciences,
Palo  Alto,  CA),  and  reverse  transcribed  into  first-strand
cDNA, using Primescript™ First-Strand cDNA Synthesis kit
(TaKaRa, Dalian, China). Each group contained three corneal
tissues. Gene-specific cDNA fragments were amplified with
DNA  polymerase  (Tiangen,  Beijing,  China),  using  the
following  primers:  matrix  metalloproteinase-9  (MMP-9)
forward 5′-CGT CGT GAT CCC CAC TTA CTA-3′ and
reverse  5′-AAG  ATG  AAC  GGG  AAC  ACA  CAG-3′;
interleukine-1β (IL-1β) forward 5′-CAG AGG ATA CCA
CTC CCA ACA-3′ and reverse 5′-TCC AGT TTG GTA GCA
TCC  ATC-3′;  glyceraldehyde-3-phosphate  dehydrogenase
(GAPDH) forward 5′-GGG CAC CGA TGG CGT TGA GT-3′
and reverse 5′-GCT GTG GTG GGG GCT GTG GA-3′. PCR
amplification  products  were  analyzed  by  agarose  gel
electrophoresis.
Antibodies and western blotting: Total protein was prepared
from  each  cornea,  using  radio  immunoprecipitation  assay
(RIPA) buffer (50 mmol/l Tris pH 7.4, 150 mmol/l NaCl, 1%
Triton  X-100,  1%  sodium  deoxycholate,  0.1%  sodium
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vector-pMSCV,  mEndo-pMSCV,  msFlk-1-pMSCV,  or
msTie2-pMSCV was added to the culture to 1×106 pfu/well
and allowed to grow 24 h before being replaced with 100 μl
of prewarmed fresh medium supplemented with 10 μl of 5 mg/
ml 3-(4,5-Dimethyl-2-thiazolyl-2,5-diphenyl-2H-tetrazolium
bromide (MTT). The contents of each retroviral particle in
every group were as follows: vehicle vector, 1×106 pfu of
vehicle retroviral particles; msFlk-1, 1×106 pfu of msFlk-1
retroviral particles; msTie2, 1×106 pfu of msTie2 retroviral
particles; mEndo, 1×106 pfu of mEndo retroviral particles;
msFlk-1/msTie2, 5×105 pfu of msFlk-1 retroviral particles and
5×105 pfu  of  msTie2  retroviral  particles;  msFlk-1/mEndo,
5×105 pfu of msFlk-1 retroviral particles and 5×105 pfu of
mEndo  retroviral  particles;  msTie2/mEndo,  5×105 pfu  of
msTie2 retroviral particles and 5×105 pfu of mEndo retroviral
particles; msFlk-1/msTie2/mEndo, 3.3×105 pfu of msFlk-1
retroviral particles, 3.3×105 pfu of msTie2 retroviral particles,
and 3.3×105 pfu of mEndo retroviral particles. Four hours later
the medium was removed and the cells dissolved in 100 μl of
DMSO. Absorbances were measured using a MultiSkan plate
reader (Molecular Devices, Sunnyvale, CA) at a wavelength
of 492 nm.dodecyl sulfate [SDS], sodium orthovanadate, and sodium
fluoride; Galen, Beijing, China), and quantified. Protein (50
µg in 15 μl loading buffer) was resolved in 10% sodium
dodecyl  sulfate  polyacrylamide  gel  electrophoresis  (SDS–
PAGE) gel and then transferred to a polyvinylidene difluoride
membrane (Millipore, Billerica, MA). The blots were blocked
in  5%  nonfat  dry  milk  dissolved  in  Tris-buffered  saline
Tween-20 (TBST; 20 mmol/l Tris, pH 7.5, 0.5 mmol/l NaCl,
0.05% Tween-20) for 1 h and then incubated with the primary
antibody  in  TBST  for  1  h,  followed  by  incubation  with
horseradish  peroxidase-conjugated  secondary  antibody
(Amersham  Biosciences,  Uppsala,  Sweden)  for  1  h.  All
incubations were done at 25 °C, and three washes with 10 ml
TBST were applied between each step. The membranes were
then  developed  with  SuperSignal  West  Femto  Maximum
Sensitivity substrate (Pierce Biotechnology, Rockford, IL)
and exposed to X-ray film (Kodak, Rochester, NY). The bands
were  analyzed  using  National  Institutes  of  Health  (NIH)
Figure 2. Effectiveness of multigene-based anti-angiogenic gene therapies for experimental murine corneal neovascularization (corneal NV).
Zones of inhibition of neovascularization were visible in corneas injected with retroviral virus expressing mEndo, msFlk-1, msTie2, and their
combinations.
TABLE 1. INHIBITION OF CORNEAL NV BY RETROVIRAL VIRUS EXPRESSING MSFLK-1, MSTIE2, OR MENDO (MEAN±SD).
Neovascularization score
Groups
Number of
eyes
p (versus
saline)
p (versus
vehicle vector)
Saline 10 3.5 1 2.17±0.74 - -
vehicle vector 9 3 1.5 2.16±0.35 p>0.05 -
msFlk-1/msTie2 10 2.5 0.5 1.6±0.49 p<0.01 p<0.01
msFlk-1/mEndo 10 2.5 0.5 1.27±0.71 p<0.01 p<0.01
msTie2/mEndo 10 3.25 0.75 1.51 ±0.53 p<0.01 p<0.01
msFlk-1/msTie2/mEndo 10 2.8 0.5 1.41±0.54 p<0.01 p<0.01
Neovascularization was scored according to the distance from the limbus to the farthest end of the new vesicles: 0 (no visible
vessels  in cornea), +1.5 (1/4 distance to burn), +2 (1/3 distance to burn), +3 (1/2 distance to burn), +4 (2/3 distance to burn),
+4.5 (3/4 distance to burn) and +6 (vessels reach burn).
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Maximum Minimum MeanImage  1.62  software  (NIH,  Bethesda,  MD).  Primary
antibodies  included  anti-VEGF  antibody  (Abcam,
Cambridge,  MA),  anti-nuclear  factor  of  kappa  light
polypeptide gene enhancer in B-cells inhibitor alpha (IκBα)
antibody  (Boster,  Wuhan,  China),  anti-GAPDH  antibody
(Kangchen, Shanghai, China), anti-phosphorylated nuclear
factor-kappa B (P-NF-κB) antibody, and anti-NF-κB antibody
(Cell  Signaling  Technology,  Danvers,  MA).  All  the
experiments  reported  in  this  study  were  performed  three
times,  and  the  results  were  reproducible.  Immunoreactive
bands were quantified by using NIH Image 1.62. For each
sample, the levels of proteins of interest were normalized to
that of GAPDH.
Inflammatory  cells  infiltration  in  corneas:  Eyes  were
enucleated  7  days  after  the  alkaline  burn,  fixed  in  10%
buffered  formalin,  and  embedded  in  paraffin.  Paraffin
sections of 4 μm in thickness were deparaffinized, rehydrated,
and stained with hematoxylin and eosin staining. Three eyes
were included in each group. To count inflammatory cells,
three fields of each paraffin section in each group close to the
axis running from the center of new capillaries to the center
of the cornea were randomly selected, and the total number of
leukocytes was counted under a microscope in a blind fashion.
The total cell counts in each slide were averaged, and an
analysis of variance (ANOVA) was carried out.
Statistical  analysis:  Data  are  presented  as  mean±standard
deviation  (SD).  The  differences  between  control  and
experimental  conditions  were  evaluated  by  SPSS  11.5
software (SPSS Inc., Chicago, IL), and p<0.05 was considered
significant.
Figure 3. Combined gene therapy groups had significantly fewer inflammatory cell infiltrates. A: Histology of chemically burned corneas
stained with hematoxylin and eosin (200×). B: Three fields of each slide close to the axis running from the center of new capillaries to the
center of the cornea were selected, and the total number of inflammatory cells was counted under a microscope in a blind fashion. The total
cell counts in each slide were averaged and an analysis of variance (ANOVA) was carried out. Three sections of each group were observed
and shown as mean±SD. The asterisk indicates p<0.05, and the double asterisk indicates p<0.01, compared with the vehicle vector group.
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Anti-angiogenic genes inhibit proliferation and migration of
endothelial  cells:  We  first  measured  the  effects  of  viral
preparations on proliferation and migration of HUVEC cells.
It was not surprising, although unexpected, that infection of
HUVEC with the vehicle vector construct alone inhibited
HUVEC proliferation significantly since the “control vector
efficacy” phenomenon had been described in other systems as
well [28,29]. Except for msTie2, all other gene constructs,
alone  or  in  combination,  inhibited  HUVEC  proliferation
further when compared to the vehicle vector (Figure 1A).
Migration of HUVEC cells was significantly inhibited by
transfection  with  mEndo,  msFlk-1,  msTie2,  and  their
combinations,  as  determined  by  wound-healing  assays
(Figure 1B). While the combination of multiple genes showed
significant additive or synergistic effects over single genes in
the proliferation assay (Figure 1A), such effectd were not
observed in the migration assay (Figure 1B). The inhibitory
effect  of  the  vehicle  vector  observed  in  the  HUVEC
proliferation assay was not observed in the migration assay
either.
Prevention  of  neovascularization  in  the  cornea:  We  next
studied  the  effects  of  mEndo,  msFlk-1,  or  msTie2  gene
combinations on alkaline-induced corneal NV. At day 7 after
corneal  NV  induction  and  the  start  of  gene  therapy,  the
inhibitory effect of combined mEndo, msFlk-1, or msTie2
gene therapy was obvious when compared to eyes treated with
the vehicle vector or saline (Figure 2, Table 1). Meanwhile,
the number or density of load vessels in combined gene-
treated eyes was less than in controls (Figure 2).
DISCUSSION
Due to its noninvasive accessibility and clarity, cornea serves
an ideal target for evaluating the efficacy of various treatments
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Figure 4. Effects of gene therapy on vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP9), and interleukine-1β
(IL-1β) expression in alkaline-burned corneas. VEGF was detected by western blot (A) while MMP9 and IL-1β were detected by reverse
transcription PCR (B). GAPDH was used as the internal control in all cases. As shown by the analysis results (C) compared with the vehicle
vector group, combined gene therapy significantly downregulated the expression levels of VEGF, MMP-9, and IL-1β. Three independent
experiments were conducted, and data were shown as mean±SD. The asterisk indicates p<0.05, and the double asterisk indicates p<0.01,
compared with the group injected vehicle retroviral particles into conjunctival sac (vehicle vector group).
Inflammatory cell infiltration during the angiogenic process:
In corneal diseases, several cytokines and growth factors are
upregulated  and  induce  infiltration  of  neutrophils,
macrophages,  and  lymphocytes  [30].  Infiltration  of
inflammatory cells is often accompanied by an angiogenic
response  [31].  Therefore,  we  analyzed  the  infiltration  of
inflammatory  cells  in  this  model.  Histological  studies
revealed that corneas in all combined gene therapy groups had
significantly  fewer  inflammatory  cell  infiltrates  than  did
corneas in the saline and vehicle vector groups (Figure 3).
Effect of gene therapy on expression of angiogenic factors and
nuclear  factor-κB  pathway  activity  in  alkaline-burned
corneas: Expression of VEGF or MMP-9 and IL-1β in corneas
at day 7 after corneal NV induction was measured by using
western blotting or RT-PCR. We found that the combination
of mEndo, msFlk-1, and msTie2 genes effectively inhibited
VEGF, MMP-9, and IL-1β expression in the alkaline-burned
corneal NV model (Figure 4). Lastly we examined activity of
the  NF-κB  pathway  and  found  that  msFlk-1/mEndo  and
msFlk-1/msTie2/mEndo  significantly  reduced  NF-κB
phosphorylation and IkBα expression without changing the
total amount of NF-κB (Figure 5).against  corneal  disorders.  A  multitude  of  potential  gene
In the case of gene therapy for corneal NV, as in many
other situations, it is well recognized that targeting a single
gene often fails to ensure the theoretically predicted efficacy
[23,35-37]. We therefore investigated the possibility of better
management  of  corneal  NV  by  combining  different  anti-
angiogenic factors in the present study. We showed that the
combination of two or three genes exhibited additive effects
over a single gene in inhibiting HUVEC proliferation in vitro
(Figure 1A). This additive effect, however, was not observed
when HUVEC migration was used as the end point (Figure
1B), confirming that different pathways might be involved in
Figure 5. Measurement of nuclear factor-kappa B (NF-κB) pathway
proteins by western blotting in alkaline-burned corneas. A: Total
lysates from murine corneal tissue lysates were analyzed by western
blotting  for  their  level  of  NF-κB  activation  by  detecting
phosphorylated NF-κB (P-NF-κB), total NF-κB protein, and IκBα.
As shown by the analysis results (B), msFlk-1/mEndo and msFlk-1/
msTie2/mEndo significantly downregulated NF-κB phosphorylation
expression. Three independent experiments were conducted, and
data were shown as mean±SD. The asterisk indicates p<0.05, and the
double asterisk indicates p<0.01, compared with the vehicle vector
group.
proliferation or migration processes of endothelial cells in
response to the same stimulus [38,39].
Using an inflammation-associated corneal NV model, we
further proved that targeting neovascularization with such a
combination of genes effectively inhibited neovascularization
in the corneas. Western blotting and RT-PCR assay showed
that such anti-angiogenic activity might involve a decrease in
VEGF secretion and IL-1β/MMP-9 expression. As a principal
degrader  of  extracellular  matrix  (ECM),  MMP-9  was
proposed to facilitate the growth of new blood vessels by
breaking  down  the  ECM  and  amplifying  effects  of  other
angiogenic factors [40], thus representing a logical target for
anti-angiogenic therapy. IL-1β is one of the key mediators
involved  in  many  inflammatory  responses,  including
chemical-burn-induced corneal NV [41-43]. In the current
study, although without direct evidence, we assume that the
observed decrease in neutrophil infiltration in corneas of gene
therapy  groups  might  be  due  to  the  decrease  of  IL-1β
expression in corneas.
On the other hand, NF-κB plays an important role in
IL-1β-related  inflammatory  diseases,  including  various
corneal diseases [44,45]. In the corneal alkali burn model, NF-
κB is activated in the corneal epithelial and stromal cells
[44].  NF-κB  is  an  important  therapeutic  target  in  chronic
inflammatory diseases, enabling significant downregulation
of  macrophage-produced  pro-inflammatory  cytokines
[46-48]. NF-κB is normally sequestered in the cytoplasm by
IκB.  NF-κB  activation  requires  phosphorylation,  induced
ubiquitination, and degradation of cytoplasmic IκB. There are
conflicting data in the literature regarding the role of NF-κB
in VEGF signaling. One group has been unable to demonstrate
an effect of the NF-κB pathway on the expression of VEGF
[49]. Others have shown that the upregulation expression of
VEGF  is  regulated  by  increased  NF-κB  activity  [50,51].
Signaling via the NF-κB pathway has recently been suggested
to play a role in the transcriptional regulation of the VEGF
gene  in  various  cancer  cells  [52,53].  In  addition,
administration of NF-κB antisense oligonucleotides partially
inhibited the tumor necrosis factor-α and platelet-activating
factor-dependent  production  of  VEGF  in  human  vascular
endothelial cells [54].
In  summary,  our  study  directly  confirmed  that
combinations  of  mEndo,  msFlk-1,  and  msTie2  may  be
promising  anti-angiogenic  alternatives  for  treatment  of
corneal  diseases  with  neovascularization.  Preliminary
findings also supported a functional role for NF-κB in the
VEGF signaling pathway, but more in-depth studies should
be carried out to expound the exact mechanisms for such gene
therapy.
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